{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:52:41Z","timestamp":1786776761962,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["DP5-OD26386"],"award-info":[{"award-number":["DP5-OD26386"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["CAMS"],"award-info":[{"award-number":["CAMS"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11307-021-01627-8","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:02:31Z","timestamp":1625598151000},"page":"818-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["18F-Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Andrew","family":"Ruff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatcher J.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin R.","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esin C.","family":"Namoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Farwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-1905","authenticated-orcid":false,"given":"Mark A.","family":"Sellmyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"1","key":"1627_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000496870","volume":"46","author":"M Subklewe","year":"2019","unstructured":"Subklewe M, Von Bergwelt-Baildon M, Humpe A (2019) Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother 46(1):15\u201324. https:\/\/doi.org\/10.1159\/000496870","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"1627_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"26","key":"1627_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/nejmoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377(26):2545\u20132554. https:\/\/doi.org\/10.1056\/nejmoa1708566","journal-title":"N Engl J Med"},{"issue":"26","key":"1627_CR4","doi-asserted-by":"publisher","first-page":"25312544","DOI":"10.1056\/nejmoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):25312544. https:\/\/doi.org\/10.1056\/nejmoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"1627_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, J\u00e4ger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak \u00d6, Salles G, Maziarz RT (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/nejmoa1804980","journal-title":"N Engl J Med"},{"issue":"1","key":"1627_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S14702045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a singlearm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31\u201342. https:\/\/doi.org\/10.1016\/S14702045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"10254","key":"1627_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet."},{"key":"1627_CR8","doi-asserted-by":"publisher","unstructured":"Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A (2020) Imaging of tumour response to immunotherapy. European Radiology Experimental 4(1). https:\/\/doi.org\/10.1186\/s41747-0190134-1","DOI":"10.1186\/s41747-0190134-1"},{"issue":"1","key":"1627_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2018","unstructured":"Aide N, Hicks RJ, Tourneau CL, Lheureux S, Fanti S, Lopci E (2018) FDG PET\/CT for assessing tumour response to immunotherapy. Eur J Nucl Med Mol Imaging 46(1):238\u2013250. https:\/\/doi.org\/10.1007\/s00259-018-4171-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1627_CR10","first-page":"1412","volume":"42","author":"H Zhuang","year":"2001","unstructured":"Zhuang H, Pourdehnad E, Lambright E, Yamamoto A, Lanuti M, Li P, Mozley P, Rossman M, Albelda S, Alavi A (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. The Journal of Nuclear Medicine 42(9):1412\u20131417","journal-title":"The Journal of Nuclear Medicine"},{"issue":"1","key":"1627_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-016-2299-2","volume":"131","author":"A Tivnan","year":"2017","unstructured":"Tivnan A, Heilinger T, Lavelle EC, Prehn JH (2017) Advances in immunotherapy for the treatment of glioblastoma. J Neuro-Oncol 131(1):1\u20139. https:\/\/doi.org\/10.1007\/s11060-016-2299-2","journal-title":"J Neuro-Oncol"},{"issue":"31","key":"1627_CR12","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/jco.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541\u20133543. https:\/\/doi.org\/10.1200\/jco.2015.61.6870","journal-title":"J Clin Oncol"},{"issue":"1","key":"1627_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/bmt.2013.144","volume":"49","author":"C Bodet-Milin","year":"2013","unstructured":"Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, Guillaume T, Delaunay J, Brissot E, Moreau P, Kraeber-Bodere F, Mohty M (2013) 18F-FDG PET\/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplant 49(1):131\u2013137. https:\/\/doi.org\/10.1038\/bmt.2013.144","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"1627_CR14","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1182\/blood-200710-119164","volume":"111","author":"M Stelljes","year":"2008","unstructured":"Stelljes M, Hermann S, Albring J, K\u00f6hler G, L\u00f6ffler M, Franzius C, Poremba C, Schl\u00f6sser V, Volkmann S, Opitz C, Bremer C, Kucharzik T, Silling G, Schober O, Berdel WE, Sch\u00e4fers M, Kienast J (2008) Clinical molecular imaging in intestinal graft-versushost disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood. 111(5):2909\u20132918. https:\/\/doi.org\/10.1182\/blood-200710-119164","journal-title":"Blood."},{"issue":"22","key":"1627_CR15","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1182\/blood.v114.22.3417.3417","volume":"114","author":"J Smeltzer","year":"2009","unstructured":"Smeltzer J, Cashen AF, Zhang Q, Abboud CN, DiPersio JF, Stockerl-Goldstein K, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA (2009) Prognostic significance of PET imaging in relapsed or refractory classical Hodgkin lymphoma treated with salvage chemotherapy and autologous stem cell transplantation. Blood. 114(22):3417\u20133417. https:\/\/doi.org\/10.1182\/blood.v114.22.3417.3417","journal-title":"Blood."},{"issue":"56","key":"1627_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunotherapy Cancer 6(56):56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunotherapy Cancer"},{"issue":"12","key":"1627_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","volume":"20","author":"NN Shah","year":"2018","unstructured":"Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J (2018) Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor \u2013T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 20(12):1415\u20131418. https:\/\/doi.org\/10.1016\/j.jcyt.2018.10.003","journal-title":"Cytotherapy."},{"key":"1627_CR18","doi-asserted-by":"publisher","first-page":"504504","DOI":"10.1002\/hon.2667","volume":"37","author":"Y Zou","year":"2019","unstructured":"Zou Y, Ding C, Zhu H, Wang L, Xia Y, Liang J, Fan L, Xu W, Li J (2019) The roles of PET\/CT in predicting the prognosis of chimeric antigen receptor T cell therapy treated patients with diffuse large B cell lymphoma. Hematol Oncol 37:504504","journal-title":"Hematol Oncol"},{"key":"1627_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/edbk_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman E, Nandikolla A, Long G, Goel S, Tourneau CL (2018) Patterns of response and progression to immunotherapy. American Society of Clinical Oncology Educational Book 38:169\u2013178. https:\/\/doi.org\/10.1200\/edbk_200643","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"6","key":"1627_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"A Gallamini","year":"2014","unstructured":"Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 99(6):1107\u20131113. https:\/\/doi.org\/10.3324\/haematol.2013.103218","journal-title":"Haematologica."},{"issue":"27","key":"1627_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer\/Dutch Hemato-Oncology Group, Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"12","key":"1627_CR22","doi-asserted-by":"publisher","first-page":"23052321","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra A, Chong EA, Hashmi SK, Neelapu SS et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):23052321\u201323052321. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.015","journal-title":"Biol Blood Marrow Transplant"},{"key":"1627_CR23","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bartlett NL, Assouline S, et al (2019) Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell therapies, and is active in treatment through multiple lines. Blood. Volume 134(Supplement_1). Abstract 6. 2019 ASH Annual Meeting. Presented December 8, 2019.","DOI":"10.1182\/blood-2019-123742"},{"issue":"1","key":"1627_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","volume":"28","author":"MA Sellmyer","year":"2020","unstructured":"Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, O\u2019Connor RS, Milone MC, Farwell MD (2020) Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Mol Ther 28(1):42\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.007","journal-title":"Mol Ther"},{"issue":"7","key":"1627_CR25","doi-asserted-by":"publisher","first-page":"eaaw5096","DOI":"10.1126\/sciadv.aaw5096","volume":"5","author":"I Minn","year":"2019","unstructured":"Minn I, Huss DJ, Ahn HH et al (2019) Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci Adv 5(7):eaaw5096. Published 2019 Jul 3. https:\/\/doi.org\/10.1126\/sciadv.aaw5096","journal-title":"Sci Adv"},{"key":"1627_CR26","doi-asserted-by":"publisher","unstructured":"Emami-Shahri N, Foster J, Kashani R et al (2018) Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nat Commun 9(1). https:\/\/doi.org\/10.1038\/s41467-018-03524-1","DOI":"10.1038\/s41467-018-03524-1"},{"issue":"5","key":"1627_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36(5):471\u2013482. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.006","journal-title":"Cancer Cell"},{"issue":"7786","key":"1627_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, Anbunathan H, Lattin J, Jones R, Tieu V, Nagaraja S, Granja J, de Bourcy CFA, Majzner R, Satpathy AT, Quake SR, Monje M, Chang HY, Mackall CL (2019) c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 576(7786):293\u2013300. https:\/\/doi.org\/10.1038\/s41586-019-1805-z","journal-title":"Nature."},{"issue":"6","key":"1627_CR29","doi-asserted-by":"publisher","first-page":"581590","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581590\u2013581590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nat Med"},{"issue":"7643","key":"1627_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, Odak A, G\u00f6nen M, Sadelain M (2017) Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 543(7643):113\u2013117. https:\/\/doi.org\/10.1038\/nature21405","journal-title":"Nature."},{"issue":"8","key":"1627_CR31","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/jci83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig 126(8):3130\u20133144. https:\/\/doi.org\/10.1172\/jci83092","journal-title":"J Clin Investig"},{"issue":"1","key":"1627_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, Ahmed R (2018) CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med 69(1):301\u2013318. https:\/\/doi.org\/10.1146\/annurev-med-012017-043208","journal-title":"Annu Rev Med"},{"issue":"2","key":"1627_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM (2016) The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 45(2):374\u2013388. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.009","journal-title":"Immunity."},{"issue":"15_suppl","key":"1627_CR34","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1200\/jco.2019.37.15_suppl.7552","volume":"37","author":"MJ Frank","year":"2019","unstructured":"Frank MJ, Hossain NM, Bukhari AA et al (2019) Monitoring ctDNA in r\/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis. J Clin Oncol 37(15_suppl):7552\u20137552. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.7552","journal-title":"J Clin Oncol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-021-01627-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T14:31:24Z","timestamp":1636468284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-021-01627-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1627"],"URL":"https:\/\/doi.org\/10.1007\/s11307-021-01627-8","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AR: none. HJB: none. ARP: none. ECN: none. MEH: AstraZeneca, Genzyme, Janssen, AbbVie: consultancy; Acerta Pharma, HOPA: research Support. SDN: Roche, Rafael, Forty Seven, Pharmacyclics, Incyte, Debiopharm, Aileron: research support; Morphosys: honorarium. EAC: Novartis, BMS, KITE: advisory boards. AB: none. MR: BMS, NanoString: consultancy; UPenn\/Novartis: patents and royalties; Abclon: consultancy, research funding. MDF: none. JS: Genmab, Adaptive, Imbrium, Atara: consultancy; Incyte, Merck: research funding; AstraZeneca, BMS, Pharmacyclics, Seattle Genetics: consultancy, research funding; TG: research funding. MAS: co-founder of Vellum Biosciences, which is supporting the development and commercialization of radiotracers to monitor gene and cell therapies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}